Patents by Inventor David Manser
David Manser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951111Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.Type: GrantFiled: June 1, 2023Date of Patent: April 9, 2024Assignee: Alkermes Pharma Ireland LimitedInventors: Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
-
Publication number: 20240091237Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.Type: ApplicationFiled: November 15, 2023Publication date: March 21, 2024Inventors: Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
-
Publication number: 20240082257Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.Type: ApplicationFiled: November 15, 2023Publication date: March 14, 2024Inventors: Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
-
Publication number: 20230310451Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.Type: ApplicationFiled: June 1, 2023Publication date: October 5, 2023Inventors: Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
-
Patent number: 11707466Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.Type: GrantFiled: June 30, 2022Date of Patent: July 25, 2023Assignee: Alkermes Pharma Ireland LimitedInventors: Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
-
Publication number: 20220354866Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.Type: ApplicationFiled: June 30, 2022Publication date: November 10, 2022Inventors: Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
-
Publication number: 20220079939Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: October 12, 2021Publication date: March 17, 2022Inventors: Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
-
Patent number: 11154552Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: June 17, 2020Date of Patent: October 26, 2021Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
-
Patent number: 10849894Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: June 29, 2018Date of Patent: December 1, 2020Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
-
Publication number: 20200316061Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (h) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: June 17, 2020Publication date: October 8, 2020Inventors: Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
-
Patent number: 10688091Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: May 20, 2019Date of Patent: June 23, 2020Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
-
Publication number: 20190269676Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: May 20, 2019Publication date: September 5, 2019Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
-
Patent number: 10159671Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.Type: GrantFiled: February 16, 2017Date of Patent: December 25, 2018Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Tarek A. Zeidan, David Manser, Kristopher Perkin, Philip Cresswell, Magali Hickey, Brian Steinberg
-
Publication number: 20180318293Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: June 29, 2018Publication date: November 8, 2018Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, JR., Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
-
Patent number: 10016415Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilization of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: August 17, 2015Date of Patent: July 10, 2018Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, Jr., Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
-
Publication number: 20180085315Abstract: Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.Type: ApplicationFiled: October 4, 2017Publication date: March 29, 2018Inventors: Gary Liversidge, David Manser, Hardik Shah, Stephen B. Ruddy, Gurvinder S. Rekhi
-
Publication number: 20170231981Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.Type: ApplicationFiled: February 16, 2017Publication date: August 17, 2017Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Tarek A. ZEIDAN, David MANSER, Kristopher Perkin, Philip CRESSWELL, Magali HICKEY, Brian STEINBERG
-
Publication number: 20160045495Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: August 17, 2015Publication date: February 18, 2016Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip CRESSWELL, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
-
Publication number: 20150216822Abstract: The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.Type: ApplicationFiled: April 17, 2015Publication date: August 6, 2015Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Deborah NEVILLE, Scott JENKINS, David MANSER
-
Patent number: 9012511Abstract: Described are compositions of stable nanoparticulate cinacalcet or a salt thereof, and methods of making and using them. The compositions exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions.Type: GrantFiled: May 18, 2011Date of Patent: April 21, 2015Assignee: Alkermes Pharma Ireland LimitedInventors: Deborah Neville, Scott Jenkins, David Manser